Organovo’s Bioprinting Platform: Enabling 3D, architecturally correct, fully human tissue for drug discovery and transplantation
Keith Murphy, Chairman and CEO at Organovo
October 5, 2016
Presented at Cell & Gene Meeting on the Mesa. San Diego, CA
Organovo designs and creates functional, three-dimensional (3D) human tissues for use in medical research and therapeutic applications. The company develops 3D human disease models through internal development and in collaboration with pharmaceutical and academic partners. Organovo’s 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at a lower cost. The company recently launched ExVive Human Liver Tissue for use in toxicology and other preclinical drug testing, with the anticipated release of the ExVive Human Kidney Tissue scheduled for Q3 2016. The company also actively conducts early research on specific tissues for therapeutic use in direct surgical applications. Organovo is changing the shape of medical research and practice.